ClinicalTrials.gg

Program

eravacycline

Also written as “Eravacycline”, “IV Eravacycline 2mg/kg” and “IV Eravacycline 1.5mg/kg”.

Its studies are mostly in Intraabdominal Infections · Appendicitis · Urinary Tract Infections · Kidney Failure, Chronic · Bacterial Infections, led by Tetraphase Pharmaceuticals.

Furthest: phase 3, since Apr 29, 201310 company-led studies, 1 open or runningNext primary completion: Feb 17, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tetraphase Pharmaceuticals101 open or runningphase 3since Apr 29, 2013Dec 21, 2010Feb 17, 2029phase 2 · NCT06794541

Also a collaborator on its studies: innoviva-specialty-therapeutics.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2010First study: phase 2 study in Complicated Intra-abdominal InfectionFirst studyNCT01265784 · 143 enrolled · United States, Bulgaria, India and more
  2. Apr 29, 2013Phase 3 study in Complicated Intra-abdominal InfectionsNCT01844856 · 541 enrolled · United States, Argentina, Bulgaria and more
  3. Sep 10, 2013Phase 1 study in Normal Drug ToleranceNCT01989949 · 20 enrolled · United States
  4. Oct 28, 2013Phase 3 study in cUTINCT01978938 · 908 enrolled · United States, Bulgaria, Colombia and more
  5. May 5, 20142 phase 1 studiesNCT02135302, NCT02135276
  6. May 23, 2016Phase 3 study in Complicated Intra-abdominal InfectionsNCT02784704 · 500 enrolled · United States, Bulgaria, Czechia and more
  7. Jan 17, 2017Phase 3 study in Complicated Urinary Tract InfectionsNCT03032510 · 1,205 enrolled · United States, Austria, Bulgaria and more
  8. Sep 26, 2018Phase 1 study in Bacterial InfectionsNCT03696550 · 19 enrolled · United States
  9. Jan 15, 2025Phase 2 study in Complicated Intra-abdominal Infections (cIAI)NCT06794541 · 35 planned · United States

Ahead

  1. Feb 17, 2029Primary completion: phase 2 study in Complicated Intra-abdominal Infections (cIAI)NCT06794541

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06794541Complicated Intra-abdominal Infections (cIAI) · United States2RecruitingFeb 17, 202935
NCT03696550Bacterial Infections · United States1CompletedMar 14, 202119
NCT03032510Complicated Urinary Tract Infections · United States, Austria, Bulgaria and more3CompletedDec 20171,205
NCT02784704Complicated Intra-abdominal Infections · United States, Bulgaria, Czechia and more3CompletedMay 8, 2017500
NCT02135302Impaired Hepatic Function · United States1CompletedFeb 201424
NCT02135276Kidney Failure, Chronic1CompletedMar 201412
NCT01978938cUTI · United States, Bulgaria, Colombia and more3CompletedJun 3, 2015908
NCT01989949Normal Drug Tolerance · United States1CompletedJan 201320
NCT01844856Complicated Intra-abdominal Infections · United States, Argentina, Bulgaria and more3CompletedAug 2014541
NCT01265784Complicated Intra-abdominal Infection · United States, Bulgaria, India and more2CompletedMay 2012143

How it is read

Names in the registry

  • “Eravacycline”, 4 entries
  • “eravacycline”, 2 entries
  • “IV Eravacycline 2mg/kg”, 1 entry
  • “IV Eravacycline 1.5mg/kg”, 1 entry
  • “TP-434”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.